statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ANSS, CTLT SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ANSS, CTLT PR Newswire NEW YORK, April 29, 2024 NEW YORK...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ANSS, CTLT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, HRT, SCX SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, HRT, SCX PR Newswire NEW YORK, April 18, 2024 NEW YORK, April...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, HRT, SCX

Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. (NYSE: CTLT) by Novo Holdings, a holding and investment company that is responsible for...

Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCX SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger...

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA PR Newswire NEW YORK, April 11, 2024 NEW...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA

StockNews.com began coverage on shares of Catalent (NYSE:CTLT - Free Report) in a research note published on Wednesday. The firm issued a sell rating on the stock. A number of other brokerages have...

Catalent (NYSE:CTLT) Now Covered by StockNews.com

Bankruptcy filings in the healthcare sector rose significantly over the last three years, rising from 25 in 2021 to 46 in 2022 and 79 in 2023, which was the highest level in five years, according to...

Essential drugmaker to sell, liquidate in Chapter 11 bankruptcy

Catalent, Inc. (NYSE:CTLT - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 7,850,000 shares, an increase of...

Short Interest in Catalent, Inc. (NYSE:CTLT) Rises By 8.4%

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, SCX, EVBG, NS

Latest Ratings for CTLT
 DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Jan 2022BarclaysMaintainsOverweight Dec 2021BarclaysInitiates Coverage OnOverweight
 View More Analyst...

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Volume	1.43M
52-Wk High	$60.20
52-Wk Low	$31.45

CTLT Catalent Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals